Ser368
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser368  -  CLASP2 (human)

Site Information
LPGsLQRsRsDIDVN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2024561

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 )
Disease tissue studied:
breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , leukemia ( 8 ) , acute myelogenous leukemia ( 8 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 5 ) , acute megakaryoblastic leukemia (M7) ( 5 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 5 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 5 ) , acute myeloblastic leukemia, without maturation (M1) ( 5 ) , lung cancer ( 3 , 6 ) , non-small cell lung cancer ( 6 ) , non-small cell lung adenocarcinoma ( 3 ) , B cell lymphoma ( 5 ) , non-Hodgkin's lymphoma ( 5 ) , ovarian cancer ( 2 ) , multiple myeloma ( 5 ) , prostate cancer ( 16 , 17 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 18 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 10 ) , AML-193 (monocyte) ( 5 ) , breast ( 1 , 2 ) , Calu 6 (pulmonary) ( 6 ) , CMK (megakaryoblast) ( 5 ) , CTS (myeloid) ( 5 ) , DOHH2 ('B lymphocyte, precursor') ( 5 ) , Flp-In T-Rex-293 (epithelial) ( 7 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 7 ) , H2009 (pulmonary) ( 6 ) , H2077 (pulmonary) ( 6 ) , H2887 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HCC2279 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 6 ) , HEL (erythroid) ( 5 ) , HeLa (cervical) ( 9 , 12 , 20 ) , Jurkat (T lymphocyte) ( 4 , 19 ) , Kasumi-1 (myeloid) ( 5 ) , KG-1 (myeloid) ( 5 , 8 ) , LCLC-103H (pulmonary) ( 6 ) , LNCaP (prostate cell) ( 16 , 17 ) , lung ( 3 ) , MV4-11 (macrophage) ( 5 ) , NCI-H1568 (pulmonary) ( 6 ) , NCI-H157 (pulmonary) ( 6 ) , NCI-H1648 (pulmonary) ( 6 ) , NCI-H1650 (pulmonary) ( 11 ) , NCI-H1666 (pulmonary) ( 6 ) , NCI-H2172 (pulmonary) ( 6 ) , NCI-H2228 (pulmonary) ( 13 ) , NCI-H3255 (pulmonary) ( 14 , 15 ) , NCI-H520 (squamous) ( 6 ) , NCI-H647 (pulmonary) ( 6 ) , OPM-2 (plasma cell) ( 5 ) , ovary ( 2 ) , P31/FUJ (erythroid) ( 5 ) , PC9 (pulmonary) ( 6 ) , RL ('B lymphocyte, precursor') ( 5 ) , RPMI-8226 (plasma cell) ( 5 ) , SU-DHL-6 (B lymphocyte) ( 5 ) , U266 (plasma cell) ( 5 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

4

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

5

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

6

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

7

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

8

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

9

Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ΞΆ affinity chromatography. Cell Struct Funct 37, 39-48
22251793   Curated Info

10

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

11

Possemato A (2009) CST Curation Set: 8051; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

12

Zhou J (2009) CST Curation Set: 7616; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

13

Possemato A (2009) CST Curation Set: 7397; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

14

Possemato A (2009) CST Curation Set: 7400; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

15

Possemato A (2009) CST Curation Set: 7394; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

16

Zhou J (2009) CST Curation Set: 7216; Year: 2009; Biosample/Treatment: cell line, LNCaP/PDBu; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

17

Zhou J (2009) CST Curation Set: 7215; Year: 2009; Biosample/Treatment: cell line, LNCaP/untreated; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

18

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

19

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

20

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info